Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
09:20
Global poverty records its first increase since the introduction of the global index, affecting 1.2 billion people
09:07
North Korea launched several ballistic missiles toward the Sea of Japan, a few days after Seoul’s hypersonic test
08:58
“Fjord,” Cristian Mungiu’s film, achieves the strongest North American box-office debut among niche releases
08:56
EXCLUSIVE | October 12, 2026. Online search trends / last 24 hours
08:52
Călin Georgescu calls for the replacement of pre-trial detention / Bucharest Tribunal to decide on Monday whether he will be released from behind bars
See more news